As reported on Yahoo News, a combination therapy involving nivolumab (Opdivo) from Bristol Myers Squibb and cabozantinib (Cabometyx) from Exelixis has demonstrated substantial clinical benefit in patients with previously untreated advanced renal cell carcinoma (RCC), according to findings from a Phase III trial.
The study reported a 40% reduction in the risk of death among patients receiving the combination compared with those treated with sunitinib, a long-standing standard therapy. These results mark a meaningful advancement in first-line treatment options for advanced kidney cancer, a disease that has historically been challenging to manage.
In addition to improved overall survival, the dual regimen significantly extended progression-free survival—a key measure of how long patients live without disease worsening. Patients treated with nivolumab plus cabozantinib experienced a median progression-free survival of 16.6 months, nearly double the 8.3 months observed in the comparator arm.
The trial enrolled 651 patients with either advanced or metastatic RCC and met all its primary and secondary endpoints. The results were presented at a major international oncology conference, further underscoring the growing role of immunotherapy-based combinations in this disease setting.
Lead investigator Dr. Toni Choueiri of the Dana-Farber Cancer Institute emphasized that both agents are already widely used in oncology practice, which may accelerate adoption of the regimen. He suggested that this combination could quickly become a preferred initial treatment option given the strength and consistency of the findings.
Safety outcomes were also encouraging. The adverse event profile of the combination was described as manageable and aligned with the known side effects of each drug individually. This is an important consideration for clinicians weighing efficacy against tolerability when selecting therapy for patients with advanced disease.
Nivolumab, a PD-1 immune checkpoint inhibitor, has been a cornerstone of Bristol Myers Squibb’s oncology portfolio, generating billions of dollars in annual revenue. However, it has faced increasing competition in recent years, particularly from pembrolizumab (Keytruda), a rival therapy developed by Merck. Positive data from new combination approaches such as this one may help reinforce nivolumab’s position in a crowded immuno-oncology market.
Overall, the study adds to a growing body of evidence supporting combination strategies that pair immunotherapies with targeted agents. For patients with advanced RCC, these approaches are increasingly shifting the treatment landscape toward improved survival outcomes and longer disease control.
